Eli Lilly
Mentioned in 98 analyzed podcast episodes across 10 shows
A major Indiana-based pharmaceutical manufacturer and GLP-1 drug market leader, known for obesity and weight loss medications including Zepbound and Mounjaro, as well as Alzheimer's therapies like Donanemab. The company has gained significant market share against competitor Novo Nordisk, with strong 2026 guidance and participation in Trump administration pricing initiatives. Podcast discussions frequently cover its financial performance, competitive positioning in the GLP-1 space, pricing strategies, and emerging treatments including retitrutide and AI-assisted prescription programs.
Mentioned On
Episode Mentions
The Dr. Gabrielle Lyon Show · May 19, 2026
The Cancer Doctors Keep Missing in Young Adults - Dr. Michelle Pearlman
“Manufacturer of tirzepatide-based GLP-1 medications Zepbound and Mounjaro; compared to Novo Nordisk products for efficacy and side effect profiles”
Pod Save America · May 19, 2026
The Bruised Hand in the Cookie Jar
“Trump held $680K position as administration prepared GLP-1 drug policies benefiting the company”
Mind Pump: Raw Fitness Truth · May 16, 2026
2859: Take a Week Off and Gain 21% More Muscle — Here's the Science
“Manufacturer of tersepatide (Mounjaro), a GLP-1 medication projected to dominate the anti-obesity market through 2035”
The Joe Rogan Experience · May 14, 2026
#2499 - Marcus King
“Developing Retatrutide, a new triple agonist GLP-1 medication showing up to 24% weight loss in trials without muscle/bone density loss”
Rich Habits Podcast · May 14, 2026
Q&A: $1.3M IRA, Aging Parents & SpaceX's IPO
“Pharma company identified in AI-generated peptide investment strategy”
Pharmaceutical Executive · May 13, 2026
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
“Released late-phase obesity trial data for Mounjaro showing weight loss maintenance across patient populations”
BioSpace · May 13, 2026
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
“CEO David Ricks highest paid pharma executive in 2025 at $36.7M; company briefly reached $1T valuation”
Pharma and BioTech Daily · May 13, 2026
Pfizer's $85M Breast Cancer Deal & FDA Shakeup | Pharma and Biotech Daily
“Collaborated with Roche on European-approved Alzheimer's disease diagnostic advancement”
Platformer · May 13, 2026
The best argument I’ve heard for why AI won't take your job with Box CEO Aaron Levie
“Referenced as example of pharma company hiring lab automation software engineers to implement AI”
Mind Pump: Raw Fitness Truth · May 13, 2026
2856: BIGGEST HEALTH LIES ! Stop Following This Advice , It's Been Wrong for 40 Years | Mind Pump 2856
“Pharmaceutical company manufacturing GLP-1 medications discussed as pre-loaded option versus compound pharmacy alternatives”
硅谷101 · May 9, 2026
E235｜CAR-T能治愈癌症吗？与刘诚博士聊聊CAR-T与癌症治疗的未来
“Acquired Milkologna to enter in vivo CAR-T space; recent major deal signaling pharma commitment to next-generation CAR-T approaches”
Pharmaceutical Executive · May 8, 2026
Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA
“Manufacturer of Leqembi (lecanemab), the Alzheimer's disease monoclonal antibody with FDA-extended review for subcutaneous formulation”
Science Quickly · May 8, 2026
Influencers are obsessed with peptides. What does the science say?
“Conducting Phase 3 FDA clinical trials for retatrutide (GLP-3), a triple agonist weight loss drug more effective than existing GLP drugs”
The Ezra Klein Show · May 8, 2026
GLP-1s and the ‘Wild West’ of Wellness
“Manufacturer of tirzepatide (Zepbound, Mounjaro) and retatrutide, competing GLP-1 and multi-agonist drugs”
The Biotech Startups Podcast · May 7, 2026
🧬 Engineering a Drug Hunter: From Vet School to Big Pharma | Martin Brenner Rerelease (1/3)
“Martin's longest career stint (~10 years); shaped his scientific principles and provided mentorship, talent development, and leadership training”
Odd Lots · May 7, 2026
How an American City Can Become a Manufacturing Hub
“Announced $3.5 billion investment just outside Allentown for GLP-1 manufacturing; will create 850 jobs”
Pharma and BioTech Daily · May 7, 2026
Bayer's $2.4B Perfuse Deal Shakes Up Eye Care | Pharma and Biotech Daily
“Investing $4.5B in Indiana manufacturing complex and competing in oral obesity therapy market with Yilai”
WSJ What’s News · May 6, 2026
Samsung Hits $1 Trillion Milestone as AI Demand Soars
“Competing with Novo Nordisk in GLP-1 weight-loss drug market; launched pill at end of Q1 with strong early performance”
WSJ Minute Briefing · May 6, 2026
Samsung Joins The Trillion Dollar Club
“U.S. rival competing with Novo Nordisk in obesity drug market; launched weight loss pill end of Q1”
Stock Movers · May 6, 2026
Novo Nordisk's Pill, BMW's Struggle, Diageo Up
“Rival obesity drug competitor with injectable formulation; Novo Nordisk racing to catch up in American market”
Stock Movers · May 6, 2026
Novo Nordisk's Pill, BMW's Struggle, Diageo Up
“Launched competing obesity pill last month, posing market share risk to Novo Nordisk's weight loss drug”
On The Pen GLP-1 News · May 5, 2026
He Took Retatrutide 40mg and Proved a Point
“Foundae (orfoglutide) oral GLP-1 launch; liver safety signals; phase 3 dose reduction from 45mg to 36mg; litigation against telehealth companies”
Halftime Report · May 5, 2026
Strong Earnings Lift Stocks: How You Should Trade it 5/5/26
“Fresh buy; 156% year-over-year earnings growth; Zepbound ramping faster than expected; headed toward trillion-dollar market cap”
ZOE Science & Nutrition · Apr 30, 2026
Should you take Ozempic? The 5 things you need to know before starting GLP-1 drugs | Dr Ania Jastreboff
“Manufacturer of Mounjaro (tirzepatide), dual GLP-1/GIP receptor agonist extensively discussed in trials”
Pharma and BioTech Daily · Apr 30, 2026
AstraZeneca's £300M UK Investment Resumes Amid FDA Pilot | Pharma and Biotech Daily
“Competing in Alzheimer's disease market with Kisunla therapy against Biogen's Lakembi”
The a16z Show · Apr 29, 2026
The Shift in Global Drug Development
“Example of innovative control arm trial design using dulaglutide and terzepatide data to avoid redundant placebo arms”
Pharma and BioTech Daily · Apr 29, 2026
AstraZeneca's Breztri Asthma Approval Boosts $80B Goal | Pharma and Biotech Daily
“Partnering with Profluent on $2.2 billion deal for AI-designed recombinases in genetic medicine”
Bloomberg Tech · Apr 28, 2026
OpenAI Linked Stocks Fall on Report It Missed Targets
“Pharma company signed $2.25B deal with ProFluent for AI-driven DNA editing drug discovery”
Stock Movers · Apr 27, 2026
Verizon Earnings Preview; Domino’s Pizza Slides; Qualcomm Gains
“Acquiring Ajax Therapeutics for up to $2.3B to gain rare blood cancer treatment in phase one trials”
The a16z Show · Apr 27, 2026
Ben Horowitz on Venture Capital and AI
“Large pharmaceutical company; CEO Dave Ricks unable to get Biden administration meetings”
The David Lin Report · Apr 25, 2026
'Biggest Money Printing In Human Existence'; These Assets Blow Up Next | Jay Singh
“Contributing disproportionately to S&P 500 earnings growth alongside semiconductor companies”
Mad Money w/ Jim Cramer · Apr 24, 2026
Mad Money w/ Jim Cramer 4/24/26
“Weight loss drug script announcements disappointed; stock sold off but expected to recover with positive earnings narrative”
CNBC's "Fast Money" · Apr 24, 2026
Intel Posts Best Day Since 1987 and Counting Down to Big Tech Results 4/24/26
“Foundeo GLP-1 pill saw only 3,700 prescriptions in week 2 vs Novo's 18,000; reports earnings next week”
The a16z Show · Apr 24, 2026
AI Inside the Enterprise
“Pharmaceutical company using AI to design therapeutics, example of enterprise AI beyond tech sector”
The Compound and Friends · Apr 24, 2026
Why Nvidia is Going to 10 Trillion Dollars with Adam Parker and Rob Sechan
“Pharmaceutical company; up 10%+ in last 6 months; uncorrelated to AI semis; positioned for AI productivity gains”
Pharma and BioTech Daily · Apr 24, 2026
Regeneron Gene Therapy Approved by FDA: A Game-Changer! | Pharma and Biotech Daily
“Developing ACOTOF targeting otiferlin deficiencies for hearing loss, currently in Phase 1/2 clinical trials through 2028”
CNBC's "Fast Money" · Apr 23, 2026
Intel On The Move After Reporting Results… And “Nonchalant” Market Warning 4/23/26
“Healthcare name Karen Feinerman is long; positioned in weight loss drug market despite sector weakness”
The a16z Show · Apr 23, 2026
Martin Shkreli on AI, Pharma, and What Actually Matters
“Analyzed as facing GLP-1 patent cliff; will lose pricing power when Ozempic/Munjaro go generic; forced into perpetual innovation cycle”
Pharma and BioTech Daily · Apr 23, 2026
Amneal's $1.1B Biosimilars Move & Merck's HIV Pill | Pharma and Biotech Daily
“Competing in oral GLP-1 weight loss drug market and exited RIPK1 inhibitor partnership with Rigel Pharmaceuticals”
How I Invest with David Weisburd · Apr 22, 2026
E353: Why Biotech Is Struggling in Today’s Market (and the Future of Healthcare)
“Pharma company winning in GLP-1 market with Tirzepatide; stock has been a market darling despite pricing pressures.”
WSJ What’s News · Apr 22, 2026
Can a Chatbot Be Charged With Murder?
“Mounjaro GLP-1 medication now available through Amazon's pharmaceutical delivery program”
The Dr. Gabrielle Lyon Show · Apr 21, 2026
GLP-1 Side Effects, Risks, And Who Should Actually Be Using It | Dr. Christle Guevarra
“Manufacturer of tirzepatide (Mounjaro/Zepbound) and developer of retatrutide, third-generation GLP-1 in phase three trials”
The Rich Roll Podcast · Apr 20, 2026
In Waves & War: Marcus & Amber Capone On Psychedelic Treatment For Veteran PTSD, Rebuilding Life After War & The Mission To Heal A Generation
“Pharmaceutical company entering psychedelic space after startup biotech companies de-risk clinical development”
The Dr. Shannon Show · Apr 16, 2026
How GLP-1s Are Impacting Women's Health
“McCall mentioned Eli Lilly as likely to invest in microdosing research and tailored dosing protocols”
Armstrong & Getty On Demand · Apr 2, 2026
Oh My God I Hate The Left
“Manufacturer of Mounjaro, newly FDA-approved GLP-1 weight-loss drug with daily pill formulation”
NPR News Now · Apr 2, 2026
NPR News: 04-01-2026 8PM EDT
“FDA approved its new obesity pill Fendayo with novel ingredient orforglipron, positioning as alternative to injectable GLP-1 drugs”
PBS News Hour - Full Show · Apr 1, 2026
April 1, 2026 - PBS News Hour full episode
“FDA approved new weight loss pill Foundayo; expected to ship Monday at $25-349/month depending on insurance coverage”
Mad Money w/ Jim Cramer · Apr 1, 2026
Mad Money w/ Jim Cramer 4/1/26
“Pharmaceutical company approved Foundail GLP-1 weight loss pill and acquired Centessa Pharmaceuticals for neurological disorder research”
CNBC's "Fast Money" · Apr 1, 2026
Markets Rally Ahead of Trump’s Iran Address… And Fading The Bounce 4/1/26
“FDA approved Mounjaro oral obesity pill (Fondayo) with 12% weight loss efficacy, launching 3 months after Novo Nordisk's oral Wegovy”
CNBC's "Fast Money" · Mar 31, 2026
Stocks Rally On Optimism For End Of Iran War… And Apple’s Mag-7 Outperformance 3/31/26
“Announced $7.8 billion acquisition of Cintessa for sleep disorder drug pipeline; CEO Dave Ricks highlighted potential for new Rexin agonist class”